Eradicating Mycobacterium tuberculosis could avoid 1,500,000 deaths, 9 million new cases, and 550,000 children contracting the disease annually according to the WHO. Currently there is a $2 billion shortfall in funding to address tuberculosis.
Ensuring Chemical Structure, Biological Data and Computational Model Quality
A talk given at SLAS 2016 mon Jan 25th in San Diego
covers published work and recent forays with BIA 10-2474
Ensuring Chemical Structure, Biological Data and Computational Model Quality
A talk given at SLAS 2016 mon Jan 25th in San Diego
covers published work and recent forays with BIA 10-2474
A potential vision of the future "the ncecessary", developed for a presentation at to be provocative. The goal was to think about the near and far future and put it into context with some of the science happening now as well as disruptive steps happening in rare disease science funding. Several slides highlight 'the ideal situation'.
Pros and cons of social networking for scientistsSean Ekins
Over the past 4 years I have been using social networking tools for scientists more inspired by Antony Williams. I realized I am using many tools and there are pros and cons of them. Here is my brief summary.
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...Sean Ekins
Slides from SERMACS 2015 meeting in Memphis 2015 describing a collaborative project with SRI International and Rutgers. The work was published in PLOS ONE http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141076
Presentation from AAPS PharmSci360 (October 23, 2023) in which I describe highlights of my Springer/AAPS book Winning Grants (https://link.springer.com/book/10.1007/978-3-031-27516-6) - presenting a 'how to' guide on writing small business grants - e.g. NIH STTR and SBIR grants. Written by someone experienced in winning such grants.
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
The presentation was given at SETAC 2022 Nov 16 and describes our work on Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic Toxicity.
We generated many models that are available to license in our MegaTox software. We found that the support vector machines performed the best after assessing many algorithms for both classification and regression models.
The authors of this work are Thomas R Lane, Fabio Urbina and Sean Ekins.
The contact is sean@collaborationspharma.com
A presentation at the Global Genes rare drug development symposium on governm...Sean Ekins
This presentation from June 12 2020 gives a brief overview of my experience of 15 years of applying for government grants to fund small companies. Prior to this I had no experience of applying for such grants. The bottom line for rare disease groups / families is find a scientist that can do this or assist you. please also see www.collaborationspharma.com
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Sean Ekins
Slides from AAPS Careers session by Maren Katherina Preis, Kyle Bagin, Sean Ekins
Provides some clear steps on how you could use social media to help your career.
Oral presentation given in MEDI session at 2017 ACS in DC.
co-authors Kimberley M. Zorn, Mary A. Lingerfelt, Jair L. de Siqueira-Neto, Alex M. Clark, Sean Ekins
describes drug repurposing and machine learning - for more details see www.collaborationspharma.com
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Sean Ekins
Oral presentation at 2017 ACS in DC - given by Kimberley Zorn
co-authors include Mary A. Lingerfelt, Alex M. Clark, Sean Ekins
for more details see www.collaborationspharma.com
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchSean Ekins
Presentation given at the AAPS 2016 conference in Denver. Some of the slides are from AAPS, Some from Kudos and some from Figshare. One slide is from Tony Williams. All slides used with permission.
A potential vision of the future "the ncecessary", developed for a presentation at to be provocative. The goal was to think about the near and far future and put it into context with some of the science happening now as well as disruptive steps happening in rare disease science funding. Several slides highlight 'the ideal situation'.
Pros and cons of social networking for scientistsSean Ekins
Over the past 4 years I have been using social networking tools for scientists more inspired by Antony Williams. I realized I am using many tools and there are pros and cons of them. Here is my brief summary.
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...Sean Ekins
Slides from SERMACS 2015 meeting in Memphis 2015 describing a collaborative project with SRI International and Rutgers. The work was published in PLOS ONE http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141076
Presentation from AAPS PharmSci360 (October 23, 2023) in which I describe highlights of my Springer/AAPS book Winning Grants (https://link.springer.com/book/10.1007/978-3-031-27516-6) - presenting a 'how to' guide on writing small business grants - e.g. NIH STTR and SBIR grants. Written by someone experienced in winning such grants.
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
The presentation was given at SETAC 2022 Nov 16 and describes our work on Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic Toxicity.
We generated many models that are available to license in our MegaTox software. We found that the support vector machines performed the best after assessing many algorithms for both classification and regression models.
The authors of this work are Thomas R Lane, Fabio Urbina and Sean Ekins.
The contact is sean@collaborationspharma.com
A presentation at the Global Genes rare drug development symposium on governm...Sean Ekins
This presentation from June 12 2020 gives a brief overview of my experience of 15 years of applying for government grants to fund small companies. Prior to this I had no experience of applying for such grants. The bottom line for rare disease groups / families is find a scientist that can do this or assist you. please also see www.collaborationspharma.com
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Sean Ekins
Slides from AAPS Careers session by Maren Katherina Preis, Kyle Bagin, Sean Ekins
Provides some clear steps on how you could use social media to help your career.
Oral presentation given in MEDI session at 2017 ACS in DC.
co-authors Kimberley M. Zorn, Mary A. Lingerfelt, Jair L. de Siqueira-Neto, Alex M. Clark, Sean Ekins
describes drug repurposing and machine learning - for more details see www.collaborationspharma.com
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Sean Ekins
Oral presentation at 2017 ACS in DC - given by Kimberley Zorn
co-authors include Mary A. Lingerfelt, Alex M. Clark, Sean Ekins
for more details see www.collaborationspharma.com
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchSean Ekins
Presentation given at the AAPS 2016 conference in Denver. Some of the slides are from AAPS, Some from Kudos and some from Figshare. One slide is from Tony Williams. All slides used with permission.
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...Sean Ekins
A perspective on 12 yrs of CDD and developing products and collaborations.
A presentation given at the ACS meeting in San Diego - small business section
This presentation summarizes some early efforts on an open drug discovery collaboration between scientists in Brazil and the US. The amazing virus images were created by John Liebler and can be licensed from him http://www.artofthecell.com/animation/will-the-real-zika-virus-please-stand-up
The homology models were created with Swiss Model by Sean Ekins:
Marco Biasini, Stefan Bienert, Andrew Waterhouse, Konstantin Arnold, Gabriel Studer, Tobias Schmidt, Florian Kiefer, Tiziano Gallo Cassarino, Martino Bertoni, Lorenza Bordoli, Torsten Schwede. (2014). SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research; (1 July 2014) 42 (W1): W252-W258; doi: 10.1093/nar/gku340.
Arnold K., Bordoli L., Kopp J., and Schwede T. (2006). The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22,195-201.
Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T (2009). The SWISS-MODEL Repository and associated resources. Nucleic Acids Research. 37, D387-D392.
Guex, N., Peitsch, M.C., Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis, 30(S1), S162-S173.
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery CollaborationsSean Ekins
A talk given at SERMACS 7th Nov 2015 in Memphis, describes CDD Vault, CDD Vision and CDD Models. In addition it also describes how the software is used in large and smaller scale collaborations for drug discovery.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
TB infographic
1. WHAT IFWE
eradicated Mycobacterium tuberculosis
These would be avoided each year;
deaths
9m new cases
550,000 children with disease
$2bn shortfall in funding
Source: WHO
1,500,000